profit from every $100 of sales.
$0$100
Drugs Made In America Acquisition II Corp. Right
$0.05+0.80% today
-68.4% in 1 year
1-year low $0.051-year high $0.16
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay $1.32 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Drugs Made In America Acquisition II Corp. Right vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Drugs Made In America Acquisition II Corp. Right | 1.3× · No profit yet | ||
 BlackRock | 33.8× · Expensive | ||
 Blackstone | 48.5× · Expensive | ||
 Investor | 8.5× · Cheap | ||
 Brookfield | 71.1× · Very expensive |
AI analysis
An AI analyst reads Drugs Made In America Acquisition II Corp. Right's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- 1.3×
- –
- 0.00
- 0.0×
- 0.0×
- –
- –
- -18.6%
- 75.6%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -0.3%
- -56.4%
- 1.7%
- 0.8%
- -0.3%
- –
Growth
- –
- –
- −424.1%
- –
- +1.1%
Financial health
- -0.0×
- 0.00
- 0.0%
- –
- 0.09
- 0.09
- 0.00
How it ranks in Financial Services
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 11%of 827
Bottom 6%of 709
Top 1%of 876
Bottom 7%of 926
News
Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision lossMarketWatch · Nov 9, 2026Generate, Zealand in collaboration to develop drugs for obesity, metabolic diseasesSeeking Alpha · Oct 13, 2026As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the SqueezeYahoo Finance · Oct 11, 2026Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1sCNBC · Oct 2, 2026Beyond GLP-1 injectables, who wins the next phase for obesity drugs?Seeking Alpha · Sep 25, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
32No pass
Benjamin Graham
70Pass
Philip Fisher
40No pass
Peter Lynch
60Pass
Joel Greenblatt
33No pass
Charlie Munger
34No pass
Terry Smith
27No pass
Questions about Drugs Made In America Acquisition II Corp. Right
Is Drugs Made In America Acquisition II Corp. Right a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Drugs Made In America Acquisition II Corp. Right AI analysis
What does Drugs Made In America Acquisition II Corp. Right do?
Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It is in Asset Management.
Does Drugs Made In America Acquisition II Corp. Right pay a dividend?
No. Drugs Made In America Acquisition II Corp. Right does not pay a dividend at the moment.
How has Drugs Made In America Acquisition II Corp. Right stock done over the past year?
Down 68.4% over the past twelve months, to $0.05. It traded between $0.05 and $0.16 and is 68.4% below its high.
Who are Drugs Made In America Acquisition II Corp. Right's competitors?
The largest listed companies in the same industry are BlackRock, Blackstone, Investor and Brookfield. The peers table on this page compares their profit, growth and price with Drugs Made In America Acquisition II Corp. Right's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.